Wohl & Fruchter LLP announces investigation of Intercept Pharmaceuticals

24-02-2014 Business Wire HealthComments (0)

Intercept PharmaceuticalsPharmaceutical

Investigating possible violations of federal securities laws by officers and directors of Intercept Pharmaceuticals in connection with announcing early termination of FLINT trial of OCA.

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top